RE

Recro Pharma

- NASDAQ:REPH
Last Updated 2024-03-21

LinkedIn Profile

Access Recro Pharma historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:reph 8617597 Mar 8th, 2021 12:00AM Recro Pharma, Inc. 4.1K 39.00 Open Pharmaceuticals Mar 8th, 2021 10:30AM Mar 8th, 2021 10:30AM Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain. We believe injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. Our pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a Phase II clinical trial in post-operative pain. Based on feedback from the FDA regarding the benefit-risk profile of Dex-IN, we plan to pursue Dex-IN in peri-procedural pain. If approved, Dex-IN would also be the first approved peri-procedural pain drug in its class of drugs. As our product candidates are non-addictive, non-opioid drugs, we believe our candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory depression while maintaining meaningful analgesic effects. We believe our product candidates could provide an attractive alternative pain medication alternative to help avoid use of opioids for the more than 50 million surgical procedures that require post-operative pain medication. We currently own and operate a 97,000 square foot, DEA-licensed manufacturing facility that makes five commercial products and receives royalties associated with the sales of these products. Open Open 490 Lapp Rd Malvern Pennsylvania US 19355 Recro Pharma Pharmaceuticals & Biotechnology
nasdaq:reph 8617597 Mar 7th, 2021 12:00AM Recro Pharma, Inc. 4.1K 39.00 Open Pharmaceuticals Mar 7th, 2021 11:46AM Mar 7th, 2021 11:46AM Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain. We believe injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. Our pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a Phase II clinical trial in post-operative pain. Based on feedback from the FDA regarding the benefit-risk profile of Dex-IN, we plan to pursue Dex-IN in peri-procedural pain. If approved, Dex-IN would also be the first approved peri-procedural pain drug in its class of drugs. As our product candidates are non-addictive, non-opioid drugs, we believe our candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory depression while maintaining meaningful analgesic effects. We believe our product candidates could provide an attractive alternative pain medication alternative to help avoid use of opioids for the more than 50 million surgical procedures that require post-operative pain medication. We currently own and operate a 97,000 square foot, DEA-licensed manufacturing facility that makes five commercial products and receives royalties associated with the sales of these products. Open Open 490 Lapp Rd Malvern Pennsylvania US 19355 Recro Pharma Pharmaceuticals & Biotechnology
nasdaq:reph 8617597 Mar 6th, 2021 12:00AM Recro Pharma, Inc. 4.1K 39.00 Open Pharmaceuticals Mar 5th, 2021 09:58PM Mar 6th, 2021 11:38AM Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain. We believe injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. Our pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a Phase II clinical trial in post-operative pain. Based on feedback from the FDA regarding the benefit-risk profile of Dex-IN, we plan to pursue Dex-IN in peri-procedural pain. If approved, Dex-IN would also be the first approved peri-procedural pain drug in its class of drugs. As our product candidates are non-addictive, non-opioid drugs, we believe our candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory depression while maintaining meaningful analgesic effects. We believe our product candidates could provide an attractive alternative pain medication alternative to help avoid use of opioids for the more than 50 million surgical procedures that require post-operative pain medication. We currently own and operate a 97,000 square foot, DEA-licensed manufacturing facility that makes five commercial products and receives royalties associated with the sales of these products. Open Open 490 Lapp Rd Malvern Pennsylvania US 19355 Recro Pharma Pharmaceuticals & Biotechnology
nasdaq:reph 8617597 Mar 5th, 2021 12:00AM Recro Pharma, Inc. 4.1K 40.00 Open Pharmaceuticals Mar 5th, 2021 09:17AM Mar 5th, 2021 09:17AM Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain. We believe injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. Our pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a Phase II clinical trial in post-operative pain. Based on feedback from the FDA regarding the benefit-risk profile of Dex-IN, we plan to pursue Dex-IN in peri-procedural pain. If approved, Dex-IN would also be the first approved peri-procedural pain drug in its class of drugs. As our product candidates are non-addictive, non-opioid drugs, we believe our candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory depression while maintaining meaningful analgesic effects. We believe our product candidates could provide an attractive alternative pain medication alternative to help avoid use of opioids for the more than 50 million surgical procedures that require post-operative pain medication. We currently own and operate a 97,000 square foot, DEA-licensed manufacturing facility that makes five commercial products and receives royalties associated with the sales of these products. Open Open 490 Lapp Rd Malvern Pennsylvania US 19355 Recro Pharma Pharmaceuticals & Biotechnology
nasdaq:reph 8617597 Mar 4th, 2021 12:00AM Recro Pharma, Inc. 4.1K 40.00 Open Pharmaceuticals Mar 4th, 2021 09:15AM Mar 4th, 2021 09:15AM Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain. We believe injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. Our pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a Phase II clinical trial in post-operative pain. Based on feedback from the FDA regarding the benefit-risk profile of Dex-IN, we plan to pursue Dex-IN in peri-procedural pain. If approved, Dex-IN would also be the first approved peri-procedural pain drug in its class of drugs. As our product candidates are non-addictive, non-opioid drugs, we believe our candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory depression while maintaining meaningful analgesic effects. We believe our product candidates could provide an attractive alternative pain medication alternative to help avoid use of opioids for the more than 50 million surgical procedures that require post-operative pain medication. We currently own and operate a 97,000 square foot, DEA-licensed manufacturing facility that makes five commercial products and receives royalties associated with the sales of these products. Open Open 490 Lapp Rd Malvern Pennsylvania US 19355 Recro Pharma Pharmaceuticals & Biotechnology
nasdaq:reph 8617597 Mar 3rd, 2021 12:00AM Recro Pharma, Inc. 4.1K 40.00 Open Pharmaceuticals Mar 3rd, 2021 11:55AM Mar 3rd, 2021 11:55AM Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain. We believe injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. Our pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a Phase II clinical trial in post-operative pain. Based on feedback from the FDA regarding the benefit-risk profile of Dex-IN, we plan to pursue Dex-IN in peri-procedural pain. If approved, Dex-IN would also be the first approved peri-procedural pain drug in its class of drugs. As our product candidates are non-addictive, non-opioid drugs, we believe our candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory depression while maintaining meaningful analgesic effects. We believe our product candidates could provide an attractive alternative pain medication alternative to help avoid use of opioids for the more than 50 million surgical procedures that require post-operative pain medication. We currently own and operate a 97,000 square foot, DEA-licensed manufacturing facility that makes five commercial products and receives royalties associated with the sales of these products. Open Open 490 Lapp Rd Malvern Pennsylvania US 19355 Recro Pharma Pharmaceuticals & Biotechnology
nasdaq:reph 8617597 Mar 2nd, 2021 12:00AM Recro Pharma, Inc. 4.1K 40.00 Open Pharmaceuticals Mar 2nd, 2021 11:04AM Mar 2nd, 2021 11:04AM Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain. We believe injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. Our pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a Phase II clinical trial in post-operative pain. Based on feedback from the FDA regarding the benefit-risk profile of Dex-IN, we plan to pursue Dex-IN in peri-procedural pain. If approved, Dex-IN would also be the first approved peri-procedural pain drug in its class of drugs. As our product candidates are non-addictive, non-opioid drugs, we believe our candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory depression while maintaining meaningful analgesic effects. We believe our product candidates could provide an attractive alternative pain medication alternative to help avoid use of opioids for the more than 50 million surgical procedures that require post-operative pain medication. We currently own and operate a 97,000 square foot, DEA-licensed manufacturing facility that makes five commercial products and receives royalties associated with the sales of these products. Open Open 490 Lapp Rd Malvern Pennsylvania US 19355 Recro Pharma Pharmaceuticals & Biotechnology
nasdaq:reph 8617597 Mar 1st, 2021 12:00AM Recro Pharma, Inc. 4.1K 40.00 Open Pharmaceuticals Mar 1st, 2021 09:22AM Mar 1st, 2021 09:22AM Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain. We believe injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. Our pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a Phase II clinical trial in post-operative pain. Based on feedback from the FDA regarding the benefit-risk profile of Dex-IN, we plan to pursue Dex-IN in peri-procedural pain. If approved, Dex-IN would also be the first approved peri-procedural pain drug in its class of drugs. As our product candidates are non-addictive, non-opioid drugs, we believe our candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory depression while maintaining meaningful analgesic effects. We believe our product candidates could provide an attractive alternative pain medication alternative to help avoid use of opioids for the more than 50 million surgical procedures that require post-operative pain medication. We currently own and operate a 97,000 square foot, DEA-licensed manufacturing facility that makes five commercial products and receives royalties associated with the sales of these products. Open Open 490 Lapp Rd Malvern Pennsylvania US 19355 Recro Pharma Pharmaceuticals & Biotechnology
nasdaq:reph 8617597 Feb 28th, 2021 12:00AM Recro Pharma, Inc. 4.1K 40.00 Open Pharmaceuticals Feb 28th, 2021 10:40AM Feb 28th, 2021 10:40AM Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain. We believe injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. Our pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a Phase II clinical trial in post-operative pain. Based on feedback from the FDA regarding the benefit-risk profile of Dex-IN, we plan to pursue Dex-IN in peri-procedural pain. If approved, Dex-IN would also be the first approved peri-procedural pain drug in its class of drugs. As our product candidates are non-addictive, non-opioid drugs, we believe our candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory depression while maintaining meaningful analgesic effects. We believe our product candidates could provide an attractive alternative pain medication alternative to help avoid use of opioids for the more than 50 million surgical procedures that require post-operative pain medication. We currently own and operate a 97,000 square foot, DEA-licensed manufacturing facility that makes five commercial products and receives royalties associated with the sales of these products. Open Open 490 Lapp Rd Malvern Pennsylvania US 19355 Recro Pharma Pharmaceuticals & Biotechnology
nasdaq:reph 8617597 Feb 27th, 2021 12:00AM Recro Pharma, Inc. 4.1K 40.00 Open Pharmaceuticals Feb 26th, 2021 09:17PM Feb 26th, 2021 09:17PM Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain. We believe injectable meloxicam compares favorably to competitive therapies in extent of pain relief, onset of pain relief and duration of pain relief. Our pipeline also includes Dex-IN, a proprietary intranasal formulation of dexmedetomidine (Dex), which successfully completed a Phase II clinical trial in post-operative pain. Based on feedback from the FDA regarding the benefit-risk profile of Dex-IN, we plan to pursue Dex-IN in peri-procedural pain. If approved, Dex-IN would also be the first approved peri-procedural pain drug in its class of drugs. As our product candidates are non-addictive, non-opioid drugs, we believe our candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory depression while maintaining meaningful analgesic effects. We believe our product candidates could provide an attractive alternative pain medication alternative to help avoid use of opioids for the more than 50 million surgical procedures that require post-operative pain medication. We currently own and operate a 97,000 square foot, DEA-licensed manufacturing facility that makes five commercial products and receives royalties associated with the sales of these products. Open Open 490 Lapp Rd Malvern Pennsylvania US 19355 Recro Pharma Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.